All Stories

Actelion CEO dismisses talk of Basilea buyout bid

Nick Paul Taylor Actelion CEO Jean-Paul Clozel has dismissed the possibility of making a bid to buy Basilea Pharmaceutica. The comment quashed speculation that Actelion and Basilea ...

Pfizer looks to Russian partnership to produce some of its meds there, report says

Eric Palmer Russia's economy has gotten ugly in the past few years, but that has not dampened the enthusiasm of Big Pharma, which continues to like the look of one of the world's ...

Medicines Co. jumps on rumors of a multibillion-dollar buyout

Damian Garde Drugmaker the Medicines Company saw its shares rise as high as 14% on rumors that the company may be up for sale. FierceBiotech News

NHS watchdog takes issue with Pfizer exec’s new role on foundation trust’s board

Tracy Staton A top Pfizer executive joined the board of a National Health Service Trust in England, triggering questions about potential conflicts of interest, an NHS-focused news service ...

Surrounded by top scientists, Biden hustles up support for accelerated cancer R&D

John Carroll Vice President Joe Biden used the spotlight at the World Economic Forum in Davos to gather together some of the top players in drug R&D and highlight his push to speed ...

Takeda doubles U.K. rep ranks to boost oncology, IBD sales

Carly Helfand Takeda has its eye on some serious growth–and to help it get there, it's bringing its U.K. sales force in-house. Beginning this June, 70 contract staffers–including ...

Bristol-Myers moves forward with its $1.2B CytomX alliance

Damian Garde Bristol-Myers Squibb, working alongside CytomX Therapeutics, picked a third cancer project in a collaboration that could pay its partner as much as $ 1.2 billion. FierceBiotech ...

BMS, Lilly, Sanofi and Novartis top Big Pharma’s growth fortunes for next decade: Analysts

Tracy Staton Predicting the future–particularly when it comes to Big Pharma's prospects for growth and earnings–is a favorite pastime among industry-watchers. Even better ...

J&J halts a depression program in the shadow of fatal French trial

Damian Garde In the wake of a disastrous French clinical trial that left one volunteer dead, Johnson & Johnson has voluntarily suspended development of a similar drug until more ...

Who are the most influential people in biopharma today?

Damian Garde We'd like you to weigh in on how that certain R&D executive is blazing a trail, why a particular regulator is changing how drugmakers do business, or how one CEO ...

Crippled by 2 deaths, Zafgen says obesity drug cut weight in PhIII

John Carroll With its clinical development program for a new obesity drug in limbo following the unexplained deaths of two patients, Zafgen reported today that the troubled Phase III ...

China’s BeiGene pitches a $150M IPO to fund its cancer pipeline

Damian Garde Chinese biotech BeiGene is hoping to trade on the Nasdaq, filing for an IPO worth more than $ 150 million to support its pipeline of targeted cancer drugs. FierceBiotech ...
Page 10 of 839« First...89101112...203040...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS